Join the Trial

Welcome to the CALMA Trial on Agitation in Alzheimer’s

Join the Trial

We look forward to your participation in the trial
Here are the next two simple steps:

STEP 1: Enter zip code or your address to identify a clinical site near you

Clinical sites are currently available only in the United States
Google Maps Distance and Time Calculator

STEP 2: Once you have identified a conveniently located clinical site, please complete the form below.

Welcome to the clinical research study for Agitation in Alzheimer's Disease. Please read the following questions and mark them accordingly: 

*Physical aggression (e.g., hitting, kicking, biting, scratching, pushing). Verbal outbursts or aggression (e.g., yelling, cursing, whining, complaining). Pacing or aimless wandering. Repetitive actions or movements (e.g., tapping, fidgeting, rocking). Destructive behavior (e.g., tearing objects, throwing things, hoarding). Self-harm or inappropriate behaviors (e.g., disrobing, inappropriate touching, eating non-food items). Restlessness or inability to stay still. Excessive demands for attention or help. Making strange noises or unusual vocalizations.
**A caregiver is usually a friend or family member, such as a spouse, child, or sibling, and not always a nurse or a professional. It is an individual who aids a person with daily tasks or activities that are hampered by an illness, injury, disability, or aging.
By signing below, the individual (either the potential participant or the caregiver/legal representative) understands and consents to the potential participant’s personal health information (PHI) provided herein may be shared with the study site(s) to determine if they qualify for the clinical trial. The information will be kept private and secure.

The individual understands that consent can be withdrawn at any time.

What is CALMA?

CALMA is a multicenter Phase 2 clinical trial designed to evaluate the safety and efficacy of IGC-AD1 for treating agitation associated with Alzheimer’s dementia. 

FDA Registered Trial

Clinical Trial Identifier: NCT 05543681
Clinicaltrials.gov:
https://clinicaltrials.gov/study/NCT05543681

Eligibility Criteria


Diagnosis of Alzheimer’s Disease.


Symptoms of agitation, aggression, irritability, or restlessness.


Regular behavioral medications are permitted before and during the study.

Have a caregiver who maintains daily contact with the study participant and commits to complying with the study procedures.

Study Design

Safety Follow-Up

In Clinic Visits

Day 0, Week 2, Week 4, and Week 6

Safety Calls

Daily for the first three days, and every third day thereafter to review safety and compliance.

Thank you for submitting your information!

We will review your eligibility and either contact you directly or share your details with the clinical site. A site representative will reach out to you soon.
No thanks.